Zacks
Low Volatility ETFs to Watch Amid Major Tech Sell-Off Over AI Panic
⚠️
AI Sentiment
Highly Negative
1/10
- Home
- COR
COR
Cencora Inc.
as of 02-06-2026 4:00pm EST
$359.25
+$7.09
+2.01%
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
| Founded: | 2001 | Country: | United States |
| Employees: | N/A | City: | CONSHOHOCKEN |
| Market Cap: | 68.5B | IPO Year: | N/A |
| Target Price: | $391.31 | AVG Volume (30 days): | 1.3M |
| Analyst Decision: | Buy | Number of Analysts: | 13 |
| Dividend Yield: | Dividend Payout Frequency: | Quarterly | |
| EPS: | 8.33 | EPS Growth: | 18.64 |
| 52 Week Low/High: | $237.71 - $377.54 | Next Earning Date: | 02-04-2026 |
| Revenue: | $325,777,775,000 | Revenue Growth: | 7.45% |
| Revenue Growth (this year): | 7.19% | Revenue Growth (next year): | 6.19% |
| P/E Ratio: | 43.12 | Index: | |
| Free Cash Flow: | 3.6B | FCF Growth: | N/A |
AI-Powered COR Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 3 days ago
AI Recommendation
hold
Model Accuracy: 79.59%
79.59%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Cencora Inc. (COR)
Mauch Robert P.
Sell
President & CEO
COR Jan 20, 2026
Avg Cost/Share
$354.73
Shares
5,096
Total Value
$1,807,704.08
Owned After
66,726
SEC Form 4
Campbell Elizabeth S
Sell
Executive Vice President
COR Dec 19, 2025
Avg Cost/Share
$342.10
Shares
3,351
Total Value
$1,146,377.10
Owned After
23,891.141
SEC Form 4
Battaglia Silvana
Sell
Executive Vice President
COR Dec 19, 2025
Avg Cost/Share
$345.00
Shares
1,677
Total Value
$578,565.00
Owned After
18,796.464
SEC Form 4
Mauch Robert P.
Sell
President & CEO
COR Dec 18, 2025
Avg Cost/Share
$343.45
Shares
5,096
Total Value
$1,750,221.20
Owned After
66,726
SEC Form 4
Krikorian Lazarus
Sell
SVP & Chief Accounting Officer
COR Dec 17, 2025
Avg Cost/Share
$343.24
Shares
4,031
Total Value
$1,383,580.29
Owned After
17,154
SEC Form 4
Mauch Robert P.
Sell
President & CEO
COR Nov 18, 2025
Avg Cost/Share
$366.64
Shares
5,096
Total Value
$1,868,397.44
Owned After
66,726
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Mauch Robert P. | COR | President & CEO | Jan 20, 2026 | Sell | $354.73 | 5,096 | $1,807,704.08 | 66,726 | |
| Campbell Elizabeth S | COR | Executive Vice President | Dec 19, 2025 | Sell | $342.10 | 3,351 | $1,146,377.10 | 23,891.141 | |
| Battaglia Silvana | COR | Executive Vice President | Dec 19, 2025 | Sell | $345.00 | 1,677 | $578,565.00 | 18,796.464 | |
| Mauch Robert P. | COR | President & CEO | Dec 18, 2025 | Sell | $343.45 | 5,096 | $1,750,221.20 | 66,726 | |
| Krikorian Lazarus | COR | SVP & Chief Accounting Officer | Dec 17, 2025 | Sell | $343.24 | 4,031 | $1,383,580.29 | 17,154 | |
| Mauch Robert P. | COR | President & CEO | Nov 18, 2025 | Sell | $366.64 | 5,096 | $1,868,397.44 | 66,726 |
Latest Cencora Inc. News
COR Breaking Stock News: Dive into COR Ticker-Specific Updates for Smart Investing
MT Newswires
Evercore ISI Adjusts Price Target on Cencora to $420 From $440, Maintains Outperform Rating
📊
AI Sentiment
Positive
7/10
Barrons.com
Cardinal Health Stock Jumps After Earnings. Its CEO Explains What Went Right.
📈
AI Sentiment
Highly Positive
9/10
StockStory
COR Q4 Deep Dive: Specialty Expansion and OneOncology Drive Strategic Shifts
➖
AI Sentiment
Neutral
4/10
Compare COR vs Leading Stocks
See how COR stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "COR Cencora Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.